| Literature DB >> 23688143 |
Nicola McCleary1, Eilidh M Duncan, Fiona Stewart, Jill J Francis.
Abstract
Key components of healthcare interventions include 'active ingredients' (intervention components that can be specifically linked to effects on outcomes such that, were they omitted, the intervention would be ineffective). These should be reported in titles and abstracts of published reports of randomized controlled trials (RCTs). However, reporting of non-pharmacologic interventions (NPIs), particularly behaviour change interventions (BCIs), is difficult, owing to their complexity. This illustrative review compares how pharmacologic interventions (PIs), NPIs and BCIs are specified in titles and abstracts to clarify how reporting of NPIs and BCIs can be improved. MEDLINE and Embase were searched for RCTs published in the British Medical Journal, The Journal of the American Medical Association, The New England Journal of Medicine, The Lancet and Annals of Behavioral Medicine from 2009 to March 2011. All types of intervention, participant and outcome were included. A random sample of 198 studies (sampled proportionally from included journals) stratified by intervention type (PI/NPI) was taken: 98 evaluated PIs, 96 evaluated NPIs and four evaluated both. Studies were coded for the presence or absence of key components. The frequency data were analyzed using the chi-square test. Active ingredients were named in 88% titles and 95% abstracts of PI reports, and in 51% titles and 71% abstracts of NPI reports, with a significant association between intervention type and reporting of active ingredients in titles (χ2(1) = 28.90; P < 0.001) and abstracts (χ2(1) = 16.94; P < 0.001). Active ingredients were named in BCI reports in 37% titles and 56% abstracts, and in other NPI reports in 66% titles and 86% abstracts. There was also a significant association between intervention type and reporting of active ingredients in titles (χ2(1) = 6.68; P = 0.010) and abstracts (χ2(1) = 8.66; P = 0.003). Reporting practices also differed for such components as the trial setting and intervention provider. This review highlights the need for improved reporting of NPIs (particularly BCIs) and indicates that a set of agreed labels and definitions for complex NPIs could facilitate standardized reporting. This would ensure that interventions can be faithfully replicated and that evidence for interventions can be appropriately synthesized.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23688143 PMCID: PMC3663666 DOI: 10.1186/1745-6215-14-146
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Checklists adapted from the CONSORT extension for abstracts[1]and the CONSORT extension for non-pharmacologic interventions[2]
| Title | Randomization | Specify the use of randomization |
| Abstract | Study design | Description of trial design |
| Participants | Eligibility criteria and data collection setting | |
| Interventions | Interventions given to each group within the trial | |
| Objective | Objective or hypothesis of the trial | |
| Primary outcome | Specification of the primary outcome, result for each intervention group, estimated effect size and precision | |
| Randomization | Method used to allocate participants to intervention groups | |
| Blinding | Who was blinded to group assignment | |
| Numbers randomized and analyzed | Number of participants randomized to and analyzed in each intervention group | |
| Recruitment | Specify whether study is ongoing, closed to recruitment, or closed to follow-up | |
| Harms | Significant adverse events or side effects that occurred | |
| Conclusions | Evaluation of the results | |
| Trial registration | Trial register name and registration number | |
| Funding | Funding source | |
| Abstract (non-pharmacologic interventions) | Full description of the experimental treatment; comparator; care providers administering intervention; centres within which intervention administered; trial blinding status | |
CONSORT, Consolidated Standards of Reporting Trials.
Figure 1Flow chart of identification and selection of included studies. NPI = non-pharmacologic intervention; PI = pharmacologic intervention; RCT = randomised controlled trial.
Example of study component coding
| Active ingredients | Vitamins C and E | Not reported |
| Comparator | Placebo | Not reported |
| Health condition | Pre-eclampsia | Obesity |
| Eligibility criteria | Women with type 1 diabetes | Children |
| Objective | Prevention of pre-eclampsia | Retraining eating behaviour |
| Trial design | Randomized controlled trial | Randomized controlled trial |
Figure 2Percentage of titles reporting specific study components. NPI = non-pharmacologic intervention; PI = pharmacologic intervention. * Statistical significance of differences in percentages of studies were tested for the ‘active ingredients’ component only: P< 0.001. Note: All other study components reported by <10% of either the PI or NPI reports so are not included in figure (primary outcome; dose/intensity; frequency of treatment; duration of treatment; comparator dose/ intensity; comparator method of administration; comparator frequency of treatment; comparator duration of treatment; timing of outcome assessment; trial phase; trial registration; intervention providers).
Figure 3Percentage of abstracts reporting specific study components. NPI = non-pharmacologic intervention; PI = pharmacologic intervention. * Statistical significance of differences in percentages of studies were tested for the ‘active ingredients’ component only: P< 0.001.
Different descriptions of ‘behavioural counselling’ intervention in two studies (adapted from [[37]])
| Feedback (on diaries) | Assessment of readiness to change |
| Reinforcement | Attitude change |
| Recommendations for change | Goal setting |
| Answers to questions | Specific behavioural advice |
| General support |